High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

References

Page 1

	Year	Citations
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian, New England Journal of Medicine	2001	2.7K
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Moshe Talpaz Blood	2002	1K
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Deborah A. Thomas Blood	2003	563
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Oliver G. Ottmann Blood	2002	553
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial Xavier Thomas, Jean-Michel Boiron, Françoise Huguet, Journal of Clinical Oncology	2004	541
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Nikolas von Bubnoff, Folker Schneller, Christian Peschel, The Lancet Philadelphia-chromosome-positive LeukaemiaHematological MalignancyClinical ResistanceBcr-abl Gene MutationsMedicine	2002	459
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Blood	2003	391
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Blood	2002	308
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Blood	2005	300
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Yasuhiko Kano, Miyuki Akutsu, Saburo Tsunoda, Blood	2001	264

Page 1